The Technical Analyst
ASLAN Pharmaceuticals [ASLN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
ASLAN Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-11.13% $0.455
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 9.01 mill |
| EPS: | -2.75 |
| P/E: | -0.170 |
| Earnings Date: | Apr 26, 2024 |
| SharesOutstanding: | 19.80 mill |
| Avg Daily Volume: | 1.184 mill |
| RATING 2024-04-22 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 3/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.170 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -0.170 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0340 (-92.53%) $-0.421 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.302 - 0.608 ( +/- 33.63%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.455
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.455
Forecast 2: 16:00 - $0.455
Forecast 3: 16:00 - $0.455
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.455 (-11.13% ) |
| Volume | 11.35 mill |
| Avg. Vol. | 1.184 mill |
| % of Avg. Vol | 958.88 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ASLN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ASLN
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Last 10 Buy Signals
Latest Press Releases
2024-04-22 08:45:00 - Press Release
Aslan Pharmaceuticals Announces Positive Interim Results From Phase 2 Study Of Eblasakimab In Dupilumab-experienced Atopic Dermatitis Patients
Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (ad) studies with biologics: 60.0% of dupilumab -experienced ad patients treated with 400mg eblasakimab weekly achieved easi-90 (at least a 90% reduction in their eczema area severity index (easi) score) and 66.7% achieved a viga score of 0 or 1 (clear or almost clear skin) after 16 weeks, versus 14.3% of patients on placebo. 20% of patients treated with eblasakimab achieved easi-100 (100% reduction in their easi score) versus 0% on placebo.
2024-04-19 17:10:00 - Press Release
Aslan Pharmaceuticals Announces Receipt Of Nasdaq Notice
San mateo, calif. and singapore, april 19, 2024 (globe newswire) -- aslan pharmaceuticals (nasdaq: asln), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received a letter (the “letter”) on april 18, 2024 from the nasdaq stock market (“nasdaq”) informing the company that it failed to maintain the continued listing requirement under nasdaq listing rule 5550(b)(1) for the nasdaq capital market, which requires that a listed company's stockholders' equity be at least $2.5 million (the “stockholders' equity requirement”).
2024-04-12 08:00:00 - Press Release
Aslan Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Corporate Update
San mateo, calif. and singapore, april 12, 2024 (globe newswire) -- aslan pharmaceuticals (nasdaq: asln), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended december 31, 2023, and provided an update on recent corporate activities.
2024-03-27 08:07:00 - Press Release
Aslan Pharmaceuticals To Present At The 2nd Annual H.c. Wainwright Autoimmune And Inflammatory Disease Virtual Conference: Skin Diseases, Conditions And Disorders
San mateo, calif. and singapore, march 27, 2024 (globe newswire) -- aslan pharmaceutical (nasdaq: asln), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give a virtual company presentation at the 2nd annual h.c. wainwright autoimmune and inflammatory disease virtual conference: skin diseases, conditions and disorders, to be held virtually on thursday, march 28, 2024. aslan management will also be available for one-on-one meetings with investors on the day of the conference. please register for the event via this link or contact your representative at h.c. wainright to schedule a meeting.
2024-03-12 14:34:00 - Press Release
Aslan Pharmaceuticals Announces $5 Million Registered Direct Offering
San mateo, calif. and singapore, march 12, 2024 (globe newswire) -- aslan pharmaceuticals ltd. (nasdaq: asln), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced today announced that it has entered into a definitive agreement for the purchase and sale of 5,000,000 of the company's american depositary shares (“adss”), each ads representing twenty-five (25) ordinary shares, at an offering price of $1.00 per ads in a registered direct offering. in addition, in a concurrent private placement, the company will issue unregistered warrants to purchase up to 5,000,000 adss. the warrants have an exercise price of $1...
Latest News
2024-04-09 10:45:45 - Zacks Investment Research
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
2024-03-27 08:07:00 - GlobeNewsWire
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give a virtual company presentation at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders, to be held virtually on Thursday, March 28, 2024. ASLAN management will also be available for one-on-one meetings with investors on the day of the conference. Please register for the event via this link or contact your representative at H.C. Wainright to schedule a meeting.
2024-03-12 11:00:24 - Zacks Investment Research
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.
2024-01-02 07:00:00 - GlobeNewsWire
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
SAN MATEO, Calif. and SINGAPORE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its participation in upcoming conferences for January 2024. Listed below are meetings that management will be attending around the week of the J.P. Morgan 42nd Annual Healthcare Conference.
2023-09-07 07:00:00 - GlobeNewsWire
ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN MATEO, Calif. and SINGAPORE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give an in-person company presentation at the H.C. Wainwright 25th Annual Global Investment Conference, to be held both virtually and in-person at the Lotte New York Palace Hotel in New York City, from September 11 to 13, 2023.
2023-07-07 12:23:24 - Zacks Investment Research
ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study
ASLAN (ASLN) reports mixed results from a mid-stage study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The stock price of the company fell by 25%.
2023-07-06 08:22:00 - Market Watch
Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatment
Shares of Aslan Pharmaceuticals ASLN were down 32% premarket on Thursday after the company released new data from a clinical study of eblasakimab, an atopic dermatitis treatment. Among patients treated with the highest dose of the monoclonal antibody once every four weeks, 63% achieved at least a 75% reduction in an eczema area and severity index, the company said in a release, compared to 31% on placebo.
2023-07-05 16:30:00 - GlobeNewsWire
ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis
SAN MATEO, Calif. and SINGAPORE, July 05, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, will host a webcast to discuss the topline data from the global Phase 2b TREK-AD trial of eblasakimab in patients with moderate-to-severe atopic dermatitis on July 6, 2023, at 8:30 am ET. Management will host a question and answer session following the formal presentation.
2023-06-01 07:00:00 - GlobeNewsWire
ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
SAN MATEO, Calif. and SINGAPORE, June 01, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will present a company update at the Jefferies Global Healthcare Conference, to be held in-person in New York, NY, from June 7 to 9, 2023. Presentation details are below. ASLAN management will also be available for one-on-one meetings on the day of the presentation.
2023-04-27 11:27:37 - Zacks Investment Research
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Sanofi (SNY) have performed compared to their sector so far this year.